1 Ursula A. Matulonis, MD, Dana-Farber Cancer Institute, Boston, MA; Domenica Lorusso, MD, Fondazione Policlinico Universitario A. Gemelli, IRCCS and Catholic University of Sacred Heart, Rome, Italy; Ana Oaknin, MD, PhD, Gynaecologic Cancer Programme, Vall d'Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d'Hebron, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain; Sandro Pignata, MD, Istituto Nazionale Tumori di Napoli Fondazione G Pascale IRCCS, Naples, Italy; Andrew Dean, MD, WA Medical Oncology St John of God Subiaco Hospital, Subiaco, WA, Australia; Hannelore Denys, MD, PhD, Ghent University Hospital, Ghent, Belgium; Nicoletta Colombo, MD, European Institute of Oncology IRCCS, Milan, Italy and University of Milan-Bicocca, Milan, Italy; Toon Van Gorp, MD, University Hospital Leuven, Leuven Cancer Institute, Leuven, Belgium; Jason A. Konner, MD, Memorial Sloan Kettering Cancer Center, New York, NY; Margarita Romeo Marin, MD, Institut Català d'Oncologia, Badalona, Spain; Philipp Harter, MD, Ev. Kliniken Essen-Mitte, Essen, Germany; Conleth G. Murphy, MD, Bon Secours Hospital and Cancer Trials, Cork, Ireland; Jiuzhou Wang, PhD; Elizabeth Noble, BS; Brooke Esteves, BS; and Michael Method, MD, ImmunoGen Inc, Waltham, MA; and Robert L. Coleman, MD, US Oncology Research, Texas Oncology, The Woodlands, TX.